Jennifer H Tang1,2, Nicole L Davis3, Amanda H Corbett1, Lameck Chinula1,2, Mackenzie L Cottrell1, Yasaman Zia3, Gerald Tegha2, Frank Z Stanczyk4, Stacey Hurst3, Mina C Hosseinipour1,2, Lisa B Haddad5, Athena P Kourtis3. 1. University of North Carolina at Chapel Hill, 111 Mason Farm Road, CB #7577; Chapel Hill, NC, 27599-7577, USA. 2. UNC Project Malawi, 100 Mzimba Drive, Private Bag A104, Lilongwe, Malawi. 3. US Centers for Disease Control and Prevention, 1600 Clifton Road, Atlanta, GA, 30329, USA. 4. University of Southern California, Keck School of Medicine, Reproductive Endocrine Research Laboratory, 1321 N. Mission Road, Los Angeles, CA, 90033, USA. 5. Emory University School of Medicine, 100 Woodruff Circle, Atlanta, GA, 30322, USA.
Abstract
OBJECTIVES: Our primary objective was to compare geometric mean levonorgestrel concentrations between levonorgestrel implant users who were or were not taking the antiretroviral efavirenz, for up to 30 months after implant initiation. Our secondary objective was to evaluate the pregnancy rate among levonorgestrel implant users on efavirenz. STUDY DESIGN: We performed a subanalysis of 42 Malawian women randomized to initiate the levonorgestrel implant as part of a parent randomized clinical trial. Our subset included 30 HIV-infected women taking efavirenz and 12 HIV-uninfected women not taking efavirenz. They underwent urine pregnancy testing every 3 months and serum levonorgestrel testing at day 3 and months 1, 3, 6, 12, 18, 24, 27 and 30 after implant initiation. Geometric mean levonorgestrel concentrations were calculated for efavirenz users and non-efavirenz users at each time point. RESULTS: The geometric mean levonorgestrel concentrations were lower for efavirenz users than non-efavirenz users at every time point; the geometric mean ratio for efavirenz users:non-efavirenz users ranged from 0.60 [90% confidence interval (CI) 0.46-0.79] at 1 month to 0.27 (90% CI 0.12-0.61) at 30 months after implant insertion. No pregnancies occurred over 60 woman-years of concomitant levonorgestrel implant and efavirenz use, although 11 women had levonorgestrel concentrations < 180 pg/mL (the previously suggested minimum threshold concentration for efficacy). CONCLUSIONS: Efavirenz users had lower levonorgestrel concentrations than non-efavirenz users, and one third of our concomitant efavirenz and levonorgestrel implant users had concentrations < 180 pg/mL. Continued evaluation of the contraceptive efficacy of the levonorgestrel implant may be needed for efavirenz users. IMPLICATIONS: Among 42 Malawian women using the levonorgestrel implant for contraception, women who were taking the antiretroviral efavirenz had lower serum levonorgestrel concentrations than women who were not taking efavirenz. However, none of the women who were taking efavirenz became pregnant over 60 women-years of follow-up.
OBJECTIVES: Our primary objective was to compare geometric mean levonorgestrel concentrations between levonorgestrel implant users who were or were not taking the antiretroviral efavirenz, for up to 30 months after implant initiation. Our secondary objective was to evaluate the pregnancy rate among levonorgestrel implant users on efavirenz. STUDY DESIGN: We performed a subanalysis of 42 Malawian women randomized to initiate the levonorgestrel implant as part of a parent randomized clinical trial. Our subset included 30 HIV-infected women taking efavirenz and 12 HIV-uninfected women not taking efavirenz. They underwent urine pregnancy testing every 3 months and serum levonorgestrel testing at day 3 and months 1, 3, 6, 12, 18, 24, 27 and 30 after implant initiation. Geometric mean levonorgestrel concentrations were calculated for efavirenz users and non-efavirenz users at each time point. RESULTS: The geometric mean levonorgestrel concentrations were lower for efavirenz users than non-efavirenz users at every time point; the geometric mean ratio for efavirenz users:non-efavirenz users ranged from 0.60 [90% confidence interval (CI) 0.46-0.79] at 1 month to 0.27 (90% CI 0.12-0.61) at 30 months after implant insertion. No pregnancies occurred over 60 woman-years of concomitant levonorgestrel implant and efavirenz use, although 11 women had levonorgestrel concentrations < 180 pg/mL (the previously suggested minimum threshold concentration for efficacy). CONCLUSIONS: Efavirenz users had lower levonorgestrel concentrations than non-efavirenz users, and one third of our concomitant efavirenz and levonorgestrel implant users had concentrations < 180 pg/mL. Continued evaluation of the contraceptive efficacy of the levonorgestrel implant may be needed for efavirenz users. IMPLICATIONS: Among 42 Malawian women using the levonorgestrel implant for contraception, women who were taking the antiretroviral efavirenz had lower serum levonorgestrel concentrations than women who were not taking efavirenz. However, none of the women who were taking efavirenz became pregnant over 60 women-years of follow-up.
Authors: I Sivin; D R Mishell; S Diaz; A Biswas; F Alvarez; P Darney; P Holma; L Wan; V Brache; O Kiriwat; K Abdalla; I Campodonico; S Pasquale; M Pavez; J Schechter Journal: Contraception Date: 2000-03 Impact factor: 3.375
Authors: Michele S O'Shea; Nora E Rosenberg; Mina C Hosseinipour; Gretchen S Stuart; William C Miller; Stephen M Kaliti; Mwawi Mwale; Phylos P Bonongwe; Jennifer H Tang Journal: AIDS Care Date: 2014-11-04
Authors: David Burger; Ilse van der Heiden; Charles la Porte; Marchina van der Ende; Paul Groeneveld; Clemens Richter; Peter Koopmans; Frank Kroon; Herman Sprenger; Jan Lindemans; Paul Schenk; Ron van Schaik Journal: Br J Clin Pharmacol Date: 2006-02 Impact factor: 4.335
Authors: M Neary; M Lamorde; A Olagunju; K M Darin; C Merry; P Byakika-Kibwika; D J Back; M Siccardi; A Owen; K K Scarsi Journal: Clin Pharmacol Ther Date: 2017-05-30 Impact factor: 6.875
Authors: Kavita Nanda; Gretchen S Stuart; Jennifer Robinson; Andrew L Gray; Naomi K Tepper; Mary E Gaffield Journal: AIDS Date: 2017-04-24 Impact factor: 4.177
Authors: Rena C Patel; Maricianah Onono; Monica Gandhi; Cinthia Blat; Jill Hagey; Starley B Shade; Eric Vittinghoff; Elizabeth A Bukusi; Sara J Newmann; Craig R Cohen Journal: Lancet HIV Date: 2015-10-22 Impact factor: 12.767